


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): An 8-azaprostaglandin derivative compound represented by formula (I-a1-1)



(wherein

Y^a is -S- or -SO₂-;

ring6 is 5 or 6 membered mono-heterocyclic aryl containing hetero atoms selected from 1 to 4 nitrogen, 1 to 2 oxygen, and/or 1 to 2 sulfur atoms which may be partially or fully saturated;

R^{100} is a hydrogen atom or C1-4 alkyl;

U^{3a-1} is ring4;

ring 4 is C3-15 mono-, bi- or tri-carbocyclic aryl which may be partially or fully saturated;

ring4 may be substituted by 1 to 5 R;

R is (1) C1-10 alkyl, (2) C2-10 alkenyl, (3) C2-10 alkynyl, (4) C1-10 alkoxy, (5) C1-10 alkylthio, (6) halogen, (7) hydroxy, (8) nitro, (9) -NR¹⁵R¹⁶, (10) C1-10 alkyl substituted by C1-

10 alkoxy, (11) C1-10 alkyl substituted by 1 to 3 halogen atom(s), (12) C1-10 alkyl substituted by C1-10 alkoxy substituted by 1 to 3 halogen atom(s), (13) C1-10 alkyl substituted by -NR¹⁵R¹⁶, (14) ring5, (15) -O-ring5, (16) C1-10 alkyl substituted by ring5, (17) C2-10 alkenyl substituted by ring5, (18) C2-10 alkynyl substituted by ring5, (19) C1-10 alkoxy substituted by ring5, (20) C1-10 alkyl substituted by -O-ring5, (21) COOR¹⁷, (22) C1-10 alkoxy substituted by 1 to 4 halogen atom(s), (23) formyl, (24) C1-10 alkyl substituted by hydroxy or (25) C2-10 acyl;

R¹⁵, R¹⁶ and R¹⁷ are, each independently, (1) a hydrogen atom or (2) C1-10 alkyl;

ring5 is

(1) C3-15 mono-, bi- or tri-carbocyclic aryl which may be partially or fully saturated or
(2) 3- to 15-membered mono-, bi- or tri-heterocyclic aryl which may be partially or fully saturated and contains a hetero atom(s) selected from 1 to 4 nitrogen, 1 to 2 oxygen and/or 1 to 2 sulfur atom(s);

ring5 may be substituted by 1 to 3 substituent(s) selected from following (1)-(9):

(1) C1-10 alkyl, (2) C2-10 alkenyl, (3) C2-10 alkynyl, (4) C1-10 alkoxy, (5) C1-10 alkyl substituted by C1-10 alkoxy, (6) halogen atom, (7) hydroxy, (8) C1-10 alkyl substituted by 1 to 3 halogen atom(s), (9) C1-10 alkyl substituted by C1-10 alkoxy substituted by 1 to 3 halogen atom(s);

a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof.

Claims 2.-17. (canceled).

18. (previously presented): A pharmaceutical composition, which comprises the 8-azaprostaglandin derivative compound according to claim 1, a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof and a pharmaceutical acceptable carrier.

19. (canceled)

20. (currently amended): A method for treating ~~dysmenorrhea~~ retinal neuropathy, which comprises administering an effective amount of the 8-azaprostaglandin derivative compound according to claim 1, a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof to a subject in need of said treating.

21. (previously presented): 8-azaprostaglandin derivative compound according to claim 1, which is selected from the group consisting of:

14-oxa-14-(3,5-dichlorophenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azaprostane;

14-oxa-14-(4-nitro-3-methylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azaprostane;

14-oxa-14-(3-nitro-2-methylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azaprostane;

14-oxa-14-(3-nitro-4-methylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azaprostane;

14-oxa-14-(2-fluoro-3-trifluoromethylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane;

14-oxa-14-(3,4,5-trimethylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane;

14-oxa-14-(5,6,7,8-tetrahydronaphthalen-1-yl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane;

14-oxa-14-(2-chloro-3-trifluoromethylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane;

14-oxa-14-(3-chloro-4-fluorophenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane;

14-oxa-14-(3-trifluoromethylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane;

14-oxa-14-(3-trifluoromethoxyphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane;

14-oxa-14-(4-chloro-3-ethylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane;

14-oxa-14-(4-methylindan-7-yl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane;

14-oxa-14-(4-chloro-3-trifluoromethylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane;

14-oxa-14-(4-chloro-3,5-dimethylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane; and
14-oxa-14-(4-fluoro-3-trifluoromethylphenyl)-5-(4-carboxythiazol-2-yl)-9-oxo-
1,2,3,4,15,16,17,18,19,20-decanor-5-thia-8-azapropane; or
the pharmaceutically acceptable salt thereof or the cyclodextrin clathrate thereof.